Literature DB >> 25072963

NFAT as cancer target: mission possible?

Jiang-Jiang Qin1, Subhasree Nag1, Wei Wang2, Jianwei Zhou3, Wei-Dong Zhang4, Hui Wang5, Ruiwen Zhang6.   

Abstract

The NFAT signaling pathway regulates various aspects of cellular functions; NFAT acts as a calcium sensor, integrating calcium signaling with other pathways involved in development and growth, immune response, and inflammatory response. The NFAT family of transcription factors regulates diverse cellular functions such as cell survival, proliferation, migration, invasion, and angiogenesis. The NFAT isoforms are constitutively activated and overexpressed in several cancer types wherein they transactivate downstream targets that play important roles in cancer development and progression. Though the NFAT family has been conclusively proved to be pivotal in cancer progression, the different isoforms play distinct roles in different cellular contexts. In this review, our discussion is focused on the mechanisms that drive the activation of various NFAT isoforms in cancer. Additionally, we analyze the potential of NFAT as a valid target for cancer prevention and therapy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calcineurin–NFAT signaling; Cancer development and progression; Drug target; NFAT; NFAT regulation; Small molecule inhibitor

Mesh：

Substances：

Year:  2014        PMID： 25072963      PMCID： PMC4710172          DOI： 10.1016/j.bbcan.2014.07.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  212 in total

1.  Synergistic activation of NFAT by HIV-1 nef and the Ras/MAPK pathway.

Authors:  A Manninen; G H Renkema; K Saksela
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

2.  DHEA-induced antiproliferative effect in MCF-7 cells is androgen- and estrogen receptor-independent.

Authors:  Victoria Gayosso; Luis F Montano; Rebeca López-Marure
Journal:  Cancer J       Date:  2006 Mar-Apr       Impact factor: 3.360

3.  Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules.

Authors:  Michael H A Roehrl; Sunghyun Kang; José Aramburu; Gerhard Wagner; Anjana Rao; Patrick G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-06       Impact factor: 11.205

4.  Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells.

Authors:  Jin Ding; Jingxia Li; Caifang Xue; Kangjian Wu; Weiming Ouyang; Dongyun Zhang; Yan Yan; Chuanshu Huang
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

5.  Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.

Authors:  William H Isacoff; Jacqueline K Bendetti; John J Barstis; Abdul-Rahman Jazieh; John S Macdonald; Philip A Philip
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

Review 6.  Immunosuppressors as multidrug resistance reversal agents.

Authors:  Hamid Morjani; Claudie Madoulet
Journal:  Methods Mol Biol       Date:  2010

7.  Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.

Authors:  Takashige Masuo; Shinichi Okamura; Yajing Zhang; Masatomo Mori
Journal:  Cancer Lett       Date:  2009-05-28       Impact factor: 8.679

8.  Differential effects of black raspberry and strawberry extracts on BaPDE-induced activation of transcription factors and their target genes.

Authors:  Jingxia Li; Dongyun Zhang; Gary D Stoner; Chuanshu Huang
Journal:  Mol Carcinog       Date:  2008-04       Impact factor: 4.784

9.  Nuclear factor of activated T cells transcription factor NFATp controls superantigen-induced lethal shock.

Authors:  A V Tsytsykova; A E Goldfeld
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

10.  Nuclear factor of activated T cells balances angiogenesis activation and inhibition.

Authors:  Tetiana A Zaichuk; Emelyn H Shroff; Rebekah Emmanuel; Stephanie Filleur; Thomas Nelius; Olga V Volpert
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307
View more
  55 in total

1.  Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Bhavitavya Nijampatnam; Sadanandan E Velu; Ke-He Ruan; Ming Hu; Jianwei Zhou; Ruiwen Zhang
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

Review 2.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

3.  CD137-CD137L interaction modulates neointima formation and the phenotype transformation of vascular smooth muscle cells via NFATc1 signaling.

Authors:  Wei Zhong; Bo Li; Ping Yang; Rui Chen; Cuiping Wang; Zhongqun Wang; Chen Shao; Wei Yuan; Jinchuan Yan
Journal:  Mol Cell Biochem       Date:  2017-08-02       Impact factor: 3.396

4.  Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma.

Authors:  Zhenzhen Liu; Hongli Li; Lian He; Yu Xiang; Chengsen Tian; Can Li; Peng Tan; Ji Jing; Yanpin Tian; Lupei Du; Yun Huang; Leng Han; Minyong Li; Yubin Zhou
Journal:  Cell Chem Biol       Date:  2019-01-10       Impact factor: 8.116

5.  NFATc2 Modulates Microglial Activation in the AβPP/PS1 Mouse Model of Alzheimer's Disease.

Authors:  Gunjan D Manocha; Atreyi Ghatak; Kendra L Puig; Susan D Kraner; Christopher M Norris; Colin K Combs
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 6.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

7.  NFAT2 Isoforms Differentially Regulate Gene Expression, Cell Death, and Transformation through Alternative N-Terminal Domains.

Authors:  Pedro I Lucena; Douglas V Faget; Emilia Pachulec; Marcela C Robaina; Claudete E Klumb; Bruno K Robbs; João P B Viola
Journal:  Mol Cell Biol       Date:  2015-10-19       Impact factor: 4.272

8.  MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.

Authors:  Wei Wang; Jian-Wen Cheng; Jiang-Jiang Qin; Bo Hu; Xin Li; Bhavitavya Nijampatnam; Sadanandan E Velu; Jia Fan; Xin-Rong Yang; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2019-06-07       Impact factor: 8.679

9.  NFAT restricts osteochondroma formation from entheseal progenitors.

Authors:  Xianpeng Ge; Kelly Tsang; Lizhi He; Roberto A Garcia; Joerg Ermann; Fumitaka Mizoguchi; Minjie Zhang; Bin Zhou; Bin Zhou; Antonios O Aliprantis
Journal:  JCI Insight       Date:  2016-04

10.  NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker.

Authors:  Raul Perret; Julien Escuriol; Valérie Velasco; Laetitia Mayeur; Isabelle Soubeyran; Christophe Delfour; Sébastien Aubert; Marc Polivka; Marie Karanian; Alexandra Meurgey; Sophie Le Guellec; Noelle Weingertner; Sylvia Hoeller; Jean-Michel Coindre; Frédérique Larousserie; Gaëlle Pierron; Franck Tirode; François Le Loarer
Journal:  Mod Pathol       Date:  2020-04-23       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.